MARKET

AGE

AGE

AgeX Therapeutics
AMEX

Real-time Quotes | Nasdaq Last Sale

1.010
+0.047
+4.92%
Closed 17:01 09/17 EDT
OPEN
0.9700
PREV CLOSE
0.9626
HIGH
1.010
LOW
0.9450
VOLUME
62.70K
TURNOVER
--
52 WEEK HIGH
3.930
52 WEEK LOW
0.7501
MARKET CAP
38.32M
P/E (TTM)
-4.0368
1D
5D
1M
3M
1Y
5Y
AgeX Therapeutics Q2 EPS $(0.07), Same YoY, Sales $37.00K Down From $414.00K YoY
AgeX Therapeutics (AMEX:AGE) reported quarterly losses of $(0.07) per share. This is unchanged from the same period last year. The company reported $37.00 thousand in sales this quarter. This is a 91.06 percent decrease
Benzinga · 08/13 20:06
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
ALAMEDA, Calif., August 13, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.
Business Wire · 08/13 20:05
-- Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q2 Revenue $37,000
MT Newswires · 08/13 16:17
5 Stocks To Watch For July 26, 2021
Some of the stocks that may grab investor focus today are:
Benzinga · 07/26 08:53
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
ALAMEDA, Calif. & PITTSBURGH, July 23, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology comp...
Business Wire · 07/23 20:15
AgeX Therapeutics, LyGenesis Scrap Merger Talks; AGE Dives 12% After-Hours
MT Newswires · 07/23 16:29
AgeX Therapeutics reports Q1 results
AgeX Therapeutics (AGE): Q1 GAAP EPS of -$0.06.Revenue of $0.06M (-33.3% Y/Y)Press Release
Seekingalpha · 05/17 20:52
AgeX Therapeutics Q1 EPS $(0.05) Up From $(0.08) YoY
AgeX Therapeutics (AMEX:AGE) reported quarterly losses of $(0.05) per share. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year.
Benzinga · 05/17 20:47
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGE. Analyze the recent business situations of AgeX Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Gregory Bailey
Chief Executive Officer/Founder/Director
Michael West
Chief Financial Officer
Andrea Park
Chief Operating Officer
Nafees Malik
Vice President - Research & Development
Hal Sternberg
Independent Director
Annalisa Jenkins
Independent Director
Michael May
No Data
About AGE
AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.

Webull offers kinds of AgeX Therapeutics Inc stock information, including AMEX:AGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGE stock methods without spending real money on the virtual paper trading platform.